SH3GLB2

Across TCGA pan-cancer cohorts, SH3GLB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SH3GLB2 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SH3GLB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SH3GLB2 expression acts as an unfavorable survival marker.

SKCM, SCLC, and STAD are the cancer types where SH3GLB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.281	0.740	<.001	23	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
STAD	OS	Median	All	0.108	0.538	.020	12	view →
BLCA	OS	Median	III,IV	0.197	0.684	.013	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SH3GLB2–SKCM (DFS)

Open the SKCM breakdown →